The increasingly crowded RA market boasts many different targeted agents representing several distinct drug classes, including blockbuster TNF-α inhibitors, five non-TNF-α biologics (including the second IL-6 inhibitor, Regeneron / Sanofi’s Kevzara), and three oral Jak inhibitors, Xeljanz (Pfizer), Olumiant (Eli Lilly), and Rinvoq (AbbVie). The TNF-α inhibitors are the most widely prescribed biologics for RA refractory to conventional DMARDs, and the non-TNF-α biologics and Jak inhibitors largely compete for use in the TNF-refractory population. With the impending entry of additional Jak inhibitors (e.g., Gilead / Galapagos’s filgotinib) and biosimilars of several TNF and non-TNF biologics, marketers are facing fierce competition and increasing challenges to gain market share.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 27 country-specific interviews with thought leaders.
Epidemiology: Number of total, diagnosed, and drug-treated prevalent cases of RA; number of diagnosed prevalent cases of RA by severity.
Emerging therapies: Preregistered: 1 drug; Phase III: 3 drugs; coverage of 11 select early-phase pipeline products.